Johnson & Johnson (JNJ) : Schmidt P J Investment Management Inc reduced its stake in Johnson & Johnson by 2.37% during the most recent quarter end. The investment management company now holds a total of 68,064 shares of Johnson & Johnson which is valued at $8,416,114 after selling 1,654 shares in Johnson & Johnson , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.Johnson & Johnson makes up approximately 3.08% of Schmidt P J Investment Management Inc’s portfolio.
Other Hedge Funds, Including , Thomaspartners boosted its stake in JNJ in the latest quarter, The investment management firm added 92,935 additional shares and now holds a total of 2,356,303 shares of Johnson & Johnson which is valued at $291,356,866. Johnson & Johnson makes up approx 3.73% of Thomaspartners’s portfolio.Evanston Investments Dba Evanston Advisors reduced its stake in JNJ by selling 44 shares or 1.1% in the most recent quarter. The Hedge Fund company now holds 3,970 shares of JNJ which is valued at $493,233. Johnson & Johnson makes up approx 0.16% of Evanston Investments Dba Evanston Advisors’s portfolio.Home Federal Bank Of Tennessee boosted its stake in JNJ in the latest quarter, The investment management firm added 28 additional shares and now holds a total of 18,398 shares of Johnson & Johnson which is valued at $2,295,518. Johnson & Johnson makes up approx 1.35% of Home Federal Bank Of Tennessee’s portfolio. Lingohr Partner Asset Management Gmbh sold out all of its stake in JNJ during the most recent quarter. The investment firm sold 4,567 shares of JNJ which is valued $571,012.North Star Investment Management Corp. reduced its stake in JNJ by selling 438 shares or 0.53% in the most recent quarter. The Hedge Fund company now holds 82,747 shares of JNJ which is valued at $10,177,881. Johnson & Johnson makes up approx 1.82% of North Star Investment Management Corp.’s portfolio.
Johnson & Johnson opened for trading at $120.5 and hit $121.33 on the upside on Wednesday, eventually ending the session at $121.31, with a gain of 0.81% or 0.98 points. The heightened volatility saw the trading volume jump to 1,04,42,818 shares. Company has a market cap of $331,889 M.
On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.